NEW YORK, Jan. 10 (GenomeWeb News) - Serologicals subsidiary Chemicon International and MorphoSys signed a three-year agreement to distribute MorphoSys's research antibodies through Chemicon's sales network, said today.
Chemicon will pay MorphoSys for antibody generation, optional additional fees, and royalties on all products.
Under the agreement, MorphoSys's Antibodies by Design unit will develop antibodies from its HuCAL GOLD antibody library against targets identified and supplied by Chemicon. Chemicon will market the HuCal-based research antibodies as stand-alone products or as components of reagent kits.
The companies anticipate 100 research antibody projects per year over the life of the alliance.